With new 5-year trial data and RWE available, the client needed to update the value proposition for their orphan drug to support P&R negotiations in international markets.
The existing value proposition was a one-page document, but the client required a fully developed PPT deck presenting the value messages and supporting evidence in a visual way.
This, alongside an objection reference aid and evidence mitigation plan, were required to support ongoing and future HTA submissions.
After collating data and internal insights from the client, P4A developed a value proposition for the client’s OD.
The value proposition was then tested in interviews with 22 experts from HTA authorities across 12 markets. P4A analysed the feedback and used it to optimise the impact of the value proposition.
